
Subject: FW: Comments on the proposed list and report of the first meeting of the subcommittee of the expert committee on the selection and use of essential medicines

Attachments: Comments Dafra Pharma on report first meeting subcommittee of the expert committee on essential medicines.pdf; Annex 1 - Full Report.pdf; Annex 1 - Report plasma samples.pdf

From: Ellen Jansen [mailto:ellen.jansen@]

Sent: 10 October 2007 16:55

To: Hill, Suzanne; emlsecretariat

Subject: Comments on the proposed list and report of the first meeting of the subcommittee of the expert committee on the selection and use of essential medicines

Comments on the proposed list and report of the first meeting of the subcommittee of the expert committee on the selection and use of essential medicines

Artemether

(20 mg/ml for intramuscular administration)

(Section 6.5.3.1. Antimalarial medicines, for curative treatment)

Dear Secretary of the expert committee,

Please find enclosed the comments of Dafra Pharma on the report of the first meeting of the subcommittee of the expert committee on the selection and use of essential medicines for the application Artemether 20 mg/ml intramuscular injection as a curative antimalarial medicine.

We sincerely hope that these comments and its annexes amended contributes to our previous application in a way which will answer all open question. We would highly appreciate any comments from your side to our application.

Sincerely yours,

Dr. F.H. Jansen
Medical Director
Dafra Pharma International bvba

Dr. Kurt Naujoks
R&D Director
Dafra Pharma International bvba

Ellen Jansen
R&D Project Leader
Dafra Pharma nv
Slachthuisstraat 30/7
B-2300 Turnhout
Belgium
BTW BE 0459.676.862

Tel +32 14 61 78 20
Fax +32 14 47 29 90
RPR Turnhout

www.dafra.be

This message (including any attachments) is confidential and may be privileged. If you have received it by mistake please notify the sender by return e-mail and delete this message from your system. Any unauthorized use or dissemination of this message in whole or in part is strictly prohibited. Please note that e-mails are susceptible to change. Dafra shall not be liable for the improper or incomplete transmission of the

2007-10-12

information contained in this communication nor for any delay in its receipt or damage to your system. Dafra does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference. Any views expressed in this message are those of the individual sender and may not necessarily reflect the views of the company.